Terms: = Gastric cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
213 results:
1. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
[TBL] [Abstract] [Full Text] [Related]
2. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
Deng Z; Feng Q; Zhao D; Huang Z
Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
[TBL] [Abstract] [Full Text] [Related]
3. HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer.
Suo D; Gao X; Chen Q; Zeng T; Zhan J; Li G; Zheng Y; Zhu S; Yun J; Guan XY; Li Y
J Exp Clin Cancer Res; 2024 Apr; 43(1):106. PubMed ID: 38589927
[TBL] [Abstract] [Full Text] [Related]
4. First-line camrelizumab (a pd-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X; Xu H; Chen X; Xu T; Tian Y; Wang D; Guo F; Wang K; Jin G; Li X; Wang R; Li F; Ding Y; Tang J; Fang Y; Zhao J; Liu L; Ma L; Meng L; Hou Z; Zheng R; Liu Y; Guan N; Zhang B; Tong S; Chen S; Li X; Shu Y
Signal Transduct Target Ther; 2024 Mar; 9(1):73. PubMed ID: 38528050
[TBL] [Abstract] [Full Text] [Related]
5. Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies.
Peng H; Wu X; Zhang C; Liang Y; Cheng S; Zhang H; Shen L; Chen Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):153. PubMed ID: 38519621
[TBL] [Abstract] [Full Text] [Related]
6. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
Deng G; Zhu D; Du Z; Xue Y; Song H; Li Y
Cancer Med; 2024 Mar; 13(6):e7110. PubMed ID: 38506237
[TBL] [Abstract] [Full Text] [Related]
7. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract] [Full Text] [Related]
8. Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.
Li F; Feng Q; Tao R
Medicine (Baltimore); 2024 Mar; 103(10):e37314. PubMed ID: 38457593
[TBL] [Abstract] [Full Text] [Related]
9. Identification of ferroptosis-related subtypes, characteristics of TME infiltration and development of prognostic models in gastric cancer.
Tang X; Yu Y; Liu N; Su Y; Zhang K; Zhai Z; Chen C; Sun W; Chen D; Ling R
Int Immunopharmacol; 2024 Mar; 130():111610. PubMed ID: 38402832
[TBL] [Abstract] [Full Text] [Related]
10. Progress of pd-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
11. Identification of necroptosis-associated miRNA signature for predicting prognosis and immune landscape in stomach adenocarcinoma.
Zhang S; Liu S; Yue C; Liu Y; Zheng G; Zhang Y
Exp Cell Res; 2024 Mar; 436(1):113948. PubMed ID: 38307189
[TBL] [Abstract] [Full Text] [Related]
12. Identification of CERS5 as a molecular biomarker in pan-cancer through multiple omics integrative analysis.
Wang S; Yang J; Huang W; Yu Z; Mao Y; Feng Y; Chen J
Cell Signal; 2024 Apr; 116():111054. PubMed ID: 38244710
[TBL] [Abstract] [Full Text] [Related]
13. An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherapy outcomes.
Ying L; Hu Z; Lu Y; Tao Q; Xiong F; Shu Y; Yang Y; Qiao X; Peng C; Jiang Y; Han M; Xu M; Li X; Wang D
Oncoimmunology; 2024; 13(1):2303195. PubMed ID: 38235318
[TBL] [Abstract] [Full Text] [Related]
14. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL; van de Haar J; van den Berg JG; van Sandick JW; Kodach LL; van Dieren JM; Balduzzi S; Grootscholten C; IJsselsteijn ME; Veenhof AAFA; Hartemink KJ; Vollebergh MA; Jurdi A; Sharma S; Spickard E; Owers EC; Bartels-Rutten A; den Hartog P; de Miranda NFCC; van Leerdam ME; Haanen JBAG; Schumacher TN; Voest EE; Chalabi M
Nat Med; 2024 Feb; 30(2):519-530. PubMed ID: 38191613
[TBL] [Abstract] [Full Text] [Related]
15. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
16. Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study.
Huang W; Xiong W; Tang L; Chen C; Yuan Q; Zhang C; Zhou K; Sun Z; Zhang T; Han Z; Feng H; Liang X; Zhong Y; Deng H; Yu L; Xu Y; Wang W; Shen L; Li G; Jiang Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38179695
[TBL] [Abstract] [Full Text] [Related]
17. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer.
Huan X; Zou K; Zhang P; Ding H; Luo C; Xiang C; Xu S; Zhuang Y; Wu C; Wang Y; Wu X; Chen C; Zhang J; Yao X; Liu F; Liu S; Wu Z
Int Immunopharmacol; 2024 Jan; 127():111352. PubMed ID: 38091833
[TBL] [Abstract] [Full Text] [Related]
18. Multiplex immunohistochemistry defines two cholesterol metabolism patterns predicting immunotherapeutic outcomes in gastric cancer.
Tang W; Li G; Lin Q; Zhu Z; Wang Z; Wang Z
J Transl Med; 2023 Dec; 21(1):887. PubMed ID: 38062450
[TBL] [Abstract] [Full Text] [Related]
19. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract] [Full Text] [Related]
20. Pathologic Complete Response After gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced gastric cancer: A Case Report.
Lin Y; Chen Y; Lin S; Zheng J; Zhang X; Gan L
J Immunother; 2024 Apr; 47(3):101-105. PubMed ID: 38037229
[TBL] [Abstract] [Full Text] [Related]
[Next]
